What is the main business of Vitafarma 2007?

The main business activity of Vitafarma 2007 focuses on dispensing chemist in specialised stores.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on April 25, 2007.

Where is the headquarters located?

The headquarters is located at: ul. Kinga C. Gillette 11, 94-406 Łódź.

Who is on the management board?

The management board includes: Bożena Helena Szymańska (President of the Management Board) and Katarzyna Nockowska Stańczak (Vice President of the Management Board).

What is the share capital?

The share capital of the company is PLN 2,850,200 (approx. $769,908).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.

What was the revenue?

In 2025, the company generated total revenue of $4,179,633, representing an increase of 17.2% compared to 2024.

Yes, the company recorded a net profit of $171,315 in 2025, meaning the company decreased its profit by 1.1%.

What is the largest operating cost?

The largest operating cost category falls under other operating costs. This category amounted to $3,219,447 in 2025, representing 81% of all operating expenses.

Vitafarma 2007sp. z o.o.

Dispensing chemist in specialised stores

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2007-04-25

Share capital

2 850 200,00 PLN

Registered address

ul. Kinga C. Gillette 11, 94-406 Łódź, Poland

Electronic delivery address

AE:PL-64956-29096-DUBJE-27

Financials

Revenue history (in k)

Financial insight

Possible Estonian CIT: Equity includes Art. 28d line items, but all amounts are 0 — this may be an accounting template or the first year of the regime.

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 4.18mMedianUSD 1.76mAverageUSD 4.96m

Net profit

This companyUSD 171.32kMedianUSD 17.49kAverageUSD 77.31k

Operating costs

This companyUSD 3.96mMedianUSD 1.72mAverageUSD 4.80m

Assets

This companyUSD 2.04mMedianUSD 495.60kAverageUSD 1.69m

Industry

Bank accounts

Registered as a VAT taxpayer on 2007-06-22. Active

Erste Bank Polska
30 1090 1304 0000 0001 4957 6656
Erste Bank Polska
56 1090 1304 0000 0001 1619 2571
Erste Bank Polska
62 1090 1304 0000 0001 4957 6662

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

Public aid

Grant date	Purpose	Gross amount	Granting body
Jun 20, 2020	Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts	$2,395$2,395	Prezes Zakładu Ubezpieczeń Społecznych
May 30, 2020	Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts	$2,961$2,961	Prezes Zakładu Ubezpieczeń Społecznych
May 30, 2020	Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts	$2,804$2,804	Prezes Zakładu Ubezpieczeń Społecznych

Tenders

No recorded participation in tenders.

Regulatory authorisations

Authority	Type	Status
BDO	BDO register entry	Active

Authorized Representatives

Aleksandra Olszacka — Vice President of the Management Board

Bożena Helena Szymańska — President of the Management Board

Katarzyna Nockowska Stańczak — Vice President of the Management Board

Manner of representation

If a multi-member management board is appointed, two members of the management board acting jointly or one member of the management board acting together with a commercial proxy are authorized to make declarations on behalf of the company.

Ownership

Owner	Shares	Share value	Stake
Apteki Cefarm sp. z o.o.	43,323	$585,129.66	75.9999%
DOZ S.A.	13,681	$184,778.50	24.0001%

Beneficial owners

Person	Rights
Zbigniew Jacek Molenda (63)	Sprawowanie kontroli nad osobami prawnymi, którym łącznie przysługuje prawo własności więcej niż 25% ogólnej liczby udziałów lub akcji spółki
Jacek Romuald Szwajcowski (62)	Sprawowanie kontroli nad osobami prawnymi, którym łącznie przysługuje prawo własności więcej niż 25% ogólnej liczby udziałów lub akcji spółki

Competitors

Name	Revenue	Website
Fragalsp. z o.o.	$5,374,285.81	aptekafragal.pl
Modrzewscysp. j.	$5,602,358.99	aptekacentrum.lublin.pl
Ms-Pharmsp. z o.o. + limited partnership	$4,619,501.46	mspharm.pl
Farmjug Agsp. z o.o.	$4,213,734.86	farmjug.pl
MagmaxS.A.	$4,200,912.15	magmaxsa.pl
Adpharmasp. z o.o.	$4,026,799.19	adamed.com
Alfa Pharm - Małgorzata Janusik, Jarosław Janusiksp. j.	$3,414,382.70	aptekazielona.com.pl
Novopharm - Millersp. j.	$2,839,228.36	apteka.zyj-zdrowo.com
Pikadasp. z o.o.	$1,903,088.18	apteka-propharma.pl
Awicennasp. j.	—	a-medyczny.pl

Change history

Date	Event
2024-12-09	Address change (Marszałkowska 80, 00-517, Warszawa → Ul. Kinga C. Gillette 11, 94-406, Łódź)
2018-01-15	Share capital change (2,850,000.00 PLN → 2,850,200.00 PLN)
2015-06-26	PKD change (Removed: 10.86.Z, 10.89.Z, 21.10.Z, 49.41.Z, 63.11.Z, 63.12.Z, 64.20.Z, 68.10.Z, 68.20.Z, 70.10.Z, 70.22.Z, 73.20.Z, 77.11.Z, 77.12.Z, 77.33.Z, 77.39.Z, 78.10.Z, 78.30.Z, 82.30.Z, 82.99.Z, 85.59.B)
2013-12-04	Share capital change (50,000.00 PLN → 2,850,000.00 PLN)
2011-07-11	PKD change (Removed: 15.88.Z, 15.89.Z, 24.41.Z, 24.42.Z, 24.51.Z, 24.52.Z, 36.63.Z, 50.10.B, 51.18.Z, 51.36.Z, 51.37.Z, 51.44.Z, 51.45.Z, 51.46.Z, 51.47.Z, 51.55.Z, 51.85.Z, 51.90.Z, 52.31.Z, 52.32.Z, 52.33.Z, 52.48.A, 60.24.A, 60.24.B, 63.11.C, 63.12.C, 63.21.Z, 63.40.C, 67.13.Z, 70.20.Z, 71.10.Z, 71.21.Z, 71.33.Z, 71.34.Z, 72.10.Z, 72.2, 72.30.Z, 72.40.Z, 74.13.Z, 74.14.A, 74.40.Z, 74.87.B, 80.42.B, 90.03.Z, 93.05.Z; Added: 10.86.Z, 10.89.Z, 21.10.Z, 21.20.Z, 47.19.Z, 47.29.Z, 47.73.Z, 47.74.Z, 47.75.Z, 47.91.Z, 49.41.Z, 52.10.B, 63.11.Z, 63.12.Z, 64.20.Z, 64.99.Z, 68.10.Z, 68.20.Z, 70.10.Z, 70.22.Z, 73.20.Z, 77.11.Z, 77.12.Z, 77.33.Z, 77.39.Z, 78.10.Z, 78.30.Z, 82.30.Z, 82.99.Z, 85.59.B, 86.90.E)

FAQ

Last updated: 2026-05-27